|
Market Closed -
Euronext Paris
11:55:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.3360 EUR | +1.66% |
|
-5.62% | +12.75% |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| 09-11 | Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 33.44M | - | - | - | ||
| 363B | |||||
| 65.62B | |||||
| 12.45B | |||||
| 7.6B | |||||
| 4.49B |
- Stock Market
- Stocks
- ALCOX Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
